Episode 308: EAU 24 IMvigor011 - Outcome of ctDNA-Negative Patients Post-Cystectomy
By The Uromigos - Last Updated: April 8, 2024Matt Galsky joins the podcast to discuss the IMvigor011 trial data that was presented at the 2024 European Association of Urology congress. The study analyzed the use of adjuvant atezolizumab for high-risk MIBC in patients who are ctDNA-positive post-surgery.
Dr. Galsky serves as the Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.